Litigation Details for Tafas v. Dudas (E.D. Va. 2007)

Tafas v. Dudas (E.D. Va. 2007)

Docket		Date Filed	2007-08-22
Court	District Court, E.D. Virginia	Date Terminated	2008-04-01
Cause	28:2201 Declaratory Judgment	Assigned To	James Chris Cacheris
Jury Demand	None	Referred To	Thomas Rawles Jones Jr.
Parties	DUDAS
Patents	10,525,053
Link to Docket	External link to docket

Details for Tafas v. Dudas (E.D. Va. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-08-22				External link to document

Tafas v. Dudas, 1:07-cv-00846: Litigation Summary and Patent-Rule Analysis

Last updated: August 1, 2026

Tafas v. Dudas challenged the U.S. Patent and Trademark Office’s 2007 rules limiting continuation applications, requests for continued examination, and the number of claims that applicants could pursue without additional disclosures. The Eastern District of Virginia invalidated the rules and permanently enjoined their implementation. The Federal Circuit initially ruled that the PTO had broader rulemaking authority than the district court recognized, but the Federal Circuit later vacated its opinion after the PTO withdrew the rules. The PTO formally rescinded the rules in October 2009.

The case did not involve infringement of a pharmaceutical patent, a Paragraph IV filing, Orange Book patents, or a Hatch-Waxman dispute. Its commercial importance came from the potential effect on patent prosecution strategy, continuation practice, patent-term management, portfolio breadth, and the cost of protecting complex inventions.

What was Tafas v. Dudas about?

The case concerned whether the PTO could impose substantive limits on continuation practice and claim volume through regulations issued under the Administrative Procedure Act and the Patent Act.

The challenged rules were published on August 21, 2007, and were scheduled to take effect on November 1, 2007. The rules would have changed two areas of prosecution:

1. The number of continuation applications and requests for continued examination that an applicant could file as of right.
2. The number of claims an applicant could present without submitting an examination support document.

The rules were part of the PTO’s broader effort to reduce examination backlog and control applications that the agency viewed as excessively complex or serially prosecuted.

Who were the parties in Tafas v. Dudas?

Plaintiff: Dr. Triantafyllos Tafas

Dr. Tafas was a patent applicant and inventor who challenged the rules on the ground that they would restrict his ability to pursue continuation applications and claims arising from the same disclosure.

Intervenor: GlaxoSmithKline

GlaxoSmithKline intervened in support of Tafas. As a pharmaceutical company with large patent portfolios and substantial continuation activity, GSK had a direct interest in preserving the ability to pursue multiple claim sets over the life of a patent family.

Defendants: The USPTO and its leadership

The original caption identified Jon W. Dudas, then Under Secretary of Commerce for Intellectual Property and Director of the USPTO. After a change in PTO leadership, the case was styled Tafas v. Doll, reflecting Acting Director John J. Doll.

Court

The principal district-court proceedings occurred in the U.S. District Court for the Eastern District of Virginia, Alexandria Division.

Case element	Detail
District court	U.S. District Court for the Eastern District of Virginia
Civil action	No. 1:07-cv-00846
Original caption	Tafas v. Dudas
Later caption	Tafas v. Doll
Core dispute	Validity of 2007 PTO continuation and claim-limit rules
Primary statutes	35 U.S.C. §§ 2, 3, 120, 131, 132, 112; Administrative Procedure Act
Federal Circuit citation	Tafas v. Doll, 559 F.3d 1345 (Fed. Cir. 2009), vacated

What patent rules did Tafas challenge?

Continuation and RCE limits

The PTO’s continuation rule, generally identified as proposed or final Rule 78, would have limited an applicant to two continuation applications and one request for continued examination for each application family as of right. An applicant seeking additional continuation filings would have had to submit a petition explaining why the additional filing was necessary.

The rule implicated continuation applications, divisional applications, and requests for continued examination. It also raised questions concerning continuation practice under 35 U.S.C. § 120, which allows an application to claim the benefit of an earlier-filed application when statutory conditions are met.

Claim limits and examination support documents

The claim rule, generally identified as Rule 75, would have required an examination support document when an application contained more than five independent claims or more than 25 total claims. The applicant would have had to conduct a prior-art search, identify relevant references, explain how the claims were patentable over those references, and certify compliance with the applicable disclosure requirements.

The rule raised concerns about cost, inequitable-conduct exposure, prosecution strategy, and the practical ability of applicants to define complex inventions through multiple claim categories.

Rule area	Proposed restriction	Business effect
Continuations	Two continuation applications as of right	Reduced flexibility to pursue later claim amendments
RCEs	One RCE as of right	Greater pressure to resolve prosecution earlier
Claims	Examination support document above specified thresholds	Increased cost and potential litigation exposure
Patent families	Limits applied across related applications	Reduced ability to separate product, process, formulation, and use claims
Prosecution timing	Rules applied to pending applications	Immediate portfolio-planning consequences

What did the Eastern District of Virginia decide?

Preliminary injunction

On October 31, 2007, the district court issued a preliminary injunction preventing the PTO from implementing the rules. The injunction was entered immediately before the scheduled November 1 effective date.

The court found that the challengers had demonstrated a substantial likelihood of success and that implementation would cause irreparable harm. The court also concluded that applicants could face permanent loss of prosecution rights that could not be fully remedied after the rules took effect.

Summary judgment and permanent injunction

On April 1, 2008, Judge Cacheris granted summary judgment to Tafas and GSK and permanently enjoined the PTO from implementing the rules. The court held that the rules exceeded the PTO’s statutory authority and were substantive rather than merely procedural.

The district court’s analysis focused on two points:

• The PTO could not use rulemaking to alter substantive rights established by Congress.
• The continuation and claim limits would directly affect an applicant’s ability to obtain and define patent rights.

The court treated continuation practice and claim submission as matters governed by the Patent Act rather than as internal agency procedures. The decision rejected the PTO’s argument that the rules merely regulated the manner in which applications were examined.

District-court holding

Issue	District-court result
PTO authority to issue the rules	Insufficient statutory authority
Character of the rules	Substantive, not merely procedural
APA challenge	Rules were invalid
Preliminary injunction	Granted October 31, 2007
Summary judgment	Granted to Tafas and GSK
Permanent injunction	Entered April 1, 2008
Effective date of rules	Blocked

What did the Federal Circuit decide?

The Federal Circuit issued its decision on March 20, 2009, in Tafas v. Doll, 559 F.3d 1345. The panel took a more expansive view of the PTO’s rulemaking authority than the district court.

The Federal Circuit held that the PTO had authority to promulgate the continuation rule because the rule regulated the examination process and did not necessarily eliminate the right to file additional applications. The court also held that the claim-limit rule was not facially invalid in its entirety.

The Federal Circuit’s reasoning distinguished between rules that alter patent rights and rules that regulate the procedures through which applicants seek those rights. It viewed the PTO’s rules as procedural regulations, subject to review under the Administrative Procedure Act.

The Federal Circuit did not, however, produce a final operative framework governing the rules. The litigation changed course after the PTO withdrew the challenged rules.

Why was the Federal Circuit decision vacated?

After the Federal Circuit’s panel decision, the PTO abandoned the rule package. The agency advised the court that it would not implement the rules and that the controversy had become moot.

The Federal Circuit subsequently vacated its decision and dismissed the appeal. The vacatur removed the precedential effect of the panel opinion. The district court’s injunction remained the practical endpoint of the litigation, although the PTO’s withdrawal made further judicial resolution unnecessary.

The case is therefore cited with care:

• The Eastern District of Virginia’s 2008 decision remains an important lower-court ruling on PTO statutory authority.
• The Federal Circuit’s 2009 opinion was vacated.
• The Federal Circuit did not establish a lasting enforceable rule permitting the PTO’s 2007 limitations.
• The PTO ultimately rescinded the rules.

When did the PTO withdraw and rescind the Tafas rules?

The PTO announced withdrawal of the continuation and claim-limit rules in October 2009. The agency published a final rule rescinding the regulations on October 8, 2009. The rescission followed the Federal Circuit’s vacatur and ended the immediate litigation risk associated with the 2007 rule package.

Date	Event
August 21, 2007	Final rules published in the Federal Register
October 9, 2007	Tafas filed the district-court action
October 31, 2007	Preliminary injunction issued
November 1, 2007	Scheduled effective date; implementation blocked
April 1, 2008	District court invalidated rules and entered permanent injunction
March 20, 2009	Federal Circuit issued Tafas v. Doll
July 2009	Federal Circuit vacated its opinion and dismissed appeal after mootness
October 8, 2009	PTO rescinded the rules

How did Tafas affect pharmaceutical patent portfolios?

Tafas had direct relevance to pharmaceutical and biotechnology companies because these sectors rely heavily on continuation practice to develop layered patent protection.

A single drug or biologic portfolio may include:

• Composition-of-matter claims
• Polymorph and salt claims
• Formulation claims
• Dosage and dosing-regimen claims
• Combination-treatment claims
• Patient-selection claims
• Manufacturing and purification claims
• Device and delivery-system claims
• Biomarker and diagnostic claims

The 2007 rules could have constrained the ability to divide these claim strategies across related applications. A company might have faced pressure to disclose its full claim strategy earlier, select claim categories sooner, and prepare prior-art analyses before the commercial profile of a product was fully developed.

The rules also could have affected patent-term adjustment, prosecution timing, terminal disclaimers, continuation filing costs, and the sequencing of patents that later support Orange Book listing or litigation.

Did Tafas affect Orange Book status or Paragraph IV litigation?

No direct Orange Book or Paragraph IV ruling resulted from Tafas. The case did not determine whether a drug patent could be listed in the FDA’s Orange Book, whether a generic applicant infringed a listed patent, or whether a Paragraph IV certification was valid.

Its relevance was upstream. If the rules had survived, they could have reduced the number and timing of continuation-derived patents available for later enforcement against generic or biosimilar entrants.

Issue	Tafas impact
Orange Book listing	No direct ruling
Paragraph IV certification	No direct ruling
Hatch-Waxman litigation	No direct ruling
Patent-family strategy	Significant potential impact
Formulation patents	Potentially affected by claim and continuation limits
Method-of-use patents	Potentially affected by continuation limits
Biosimilar litigation	No direct ruling, but analogous portfolio implications

What was the commercial risk to innovators?

The principal commercial risk was loss of prosecution optionality. Pharmaceutical companies often delay final claim selection while clinical, formulation, manufacturing, and market information develops. Continuations provide a mechanism to pursue distinct claim scopes over time.

The rules could have created several risks:

1. Earlier commitment to claim strategy.
2. Higher prosecution costs for examination support documents.
3. Greater exposure to errors in prior-art analysis.
4. Reduced ability to pursue separate formulation and method-of-use claims.
5. Less flexibility to respond to competitor patents and generic design-around strategies.
6. Potential reduction in late-issued patents supporting patent-term or litigation positions.

These effects would have been most significant for products with complex patent families, multiple dosage forms, platform technologies, or evolving clinical indications.

How strong was the legal position of the PTO?

The Federal Circuit’s vacated opinion showed that the PTO had a credible statutory-authority argument. The agency relied on its authority to establish regulations governing examination and the processing of patent applications. The court’s panel decision accepted a distinction between procedural rules and substantive limits on patent rights.

The challengers’ position was stronger on the practical effect of the rules. They argued that the limits changed the rights created by the Patent Act, especially the continuation entitlement under Section 120 and the statutory claim-and-disclosure framework under Section 112.

The legal dispute can be summarized as follows:

PTO position	Tafas and GSK position
Rules regulated examination procedure	Rules restricted substantive patent rights
Applicants retained limited petition procedures	Petition procedures did not preserve statutory continuation rights
PTO needed tools to manage examination workload	Administrative efficiency could not override congressional patent provisions
Rules were within delegated authority	Congress had not authorized numerical limits of this type

The PTO’s eventual rescission prevented a definitive Supreme Court ruling on the scope of its authority.

What is the current precedential status of Tafas?

The Federal Circuit opinion, 559 F.3d 1345, was vacated. It should not be treated as controlling precedent for the proposition that the PTO may impose the specific 2007 continuation and claim limits.

The district-court decision remains relevant as persuasive authority concerning:

• The distinction between substantive and procedural patent rules.
• The limits of PTO rulemaking authority.
• The effect of agency regulations on continuation practice.
• APA review of patent-examination regulations.

The case also remains relevant in later debates over PTO rulemaking, examination efficiency, continuation filings, and agency authority.

What settlement agreement resolved Tafas?

The dispute did not end through a conventional private settlement that authorized the rules or established damages. The operative resolution came from the PTO’s withdrawal and rescission of the regulations, followed by vacatur and dismissal of the Federal Circuit appeal.

No publicly operative settlement imposed continuing restrictions on continuation applications, RCEs, or claim counts.

Key Takeaways

• Tafas v. Dudas, No. 1:07-cv-00846, challenged the PTO’s 2007 continuation and claim-limit rules.
• The Eastern District of Virginia issued a preliminary injunction on October 31, 2007.
• On April 1, 2008, the district court invalidated the rules and permanently enjoined the PTO.
• The Federal Circuit issued a broader agency-authority decision in March 2009, but later vacated it after the PTO withdrew the rules.
• The PTO formally rescinded the rules on October 8, 2009.
• The case did not involve Orange Book patents, Paragraph IV certifications, generic infringement, biosimilars, or drug-specific patent litigation.
• Its principal commercial significance was the potential restriction of continuation practice for pharmaceutical, biotechnology, formulation, method-of-use, and manufacturing patent portfolios.
• The Federal Circuit’s 559 F.3d 1345 opinion is vacated and has no continuing precedential force.

FAQs

Did Tafas eliminate continuation applications?

No. Tafas blocked and ultimately led to withdrawal of the PTO’s proposed limits. Continuation applications remained available under the Patent Act and existing PTO rules.

Did Tafas limit requests for continued examination?

No lasting RCE limit resulted from the case. The proposed one-RCE limit was rescinded with the rest of the 2007 rules.

Could the PTO later impose similar patent-prosecution limits?

The case did not establish a categorical prohibition on all PTO procedural rules. It left unresolved the precise boundary between permissible examination procedures and impermissible substantive limits on patent rights.

Did GlaxoSmithKline receive damages from the PTO?

No damages award defined the resolution. The relief was injunctive, and the challenged rules were later withdrawn and rescinded.

Is Tafas relevant to modern pharmaceutical patent litigation?

Yes. The case remains relevant to continuation strategy, patent-family design, administrative-law challenges to PTO regulations, and the ability of innovators to develop composition, formulation, manufacturing, and method-of-use protection over time.

References

1. Administrative Procedure Act, 5 U.S.C. §§ 551-706.

2. Patent Act, 35 U.S.C. §§ 2, 3, 112, 120, 131, 132.

3. Tafas v. Dudas, No. 1:07-cv-846, 2008 WL 2753034 (E.D. Va. Apr. 1, 2008).

4. Tafas v. Doll, 559 F.3d 1345 (Fed. Cir. 2009), vacated.

5. U.S. Patent and Trademark Office. (2007, August 21). Changes to practice for continuing applications, requests for continued examination practice, and applications containing patentably indistinct claims. Federal Register, 72, 46716.

6. U.S. Patent and Trademark Office. (2009, October 8). Rescission of the rules governing continuing applications, requests for continued examination practice, and applications containing patentably indistinct claims. Federal Register.